Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 28th Annual Global Investment Conference September 11, 2026 7:00 AM EDT
Company Participants
Jacqueline Shea – CEO, President & Director
Presentation
Unknown Analyst
Hello, everyone, and thank you for joining us today. It’s my pleasure to introduce Dr. Jacqueline Shea, President and CEO of Inovio Pharmaceuticals. Jacqui has more than 25 years of experience across the life sciences and biotech industries and has led Inovio since 2022.
Prior to becoming CEO, she has served as the company’s Chief Operating Officer and earlier in her career, held leadership roles at Aeras and Emergent BioSolutions with much of her work focused on the development of vaccines and therapies for infectious diseases. She holds a PhD from the National Institute for Medical Research in the U.K. and currently serves on the Board of Trustees of the Sabin Vaccine Institute.
Jacqui, thanks very much for coming today and joining us, and I’ll turn it over to you.
Jacqueline Shea
CEO, President & Director
Thank you. It’s a pleasure to be here today and tell you about some of the exciting work that we’re doing here at Inovio. So before I move into the presentation in full, this is just a standard slide that says during the presentation, I’ll be making forward-looking statements, and I refer you to our most recently filed 10-Q and 10-K documents for further details.
So to provide you a quick overview of Inovio, we’re a clinical stage biotech company. We’re focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer and infectious diseases. Our lead program, INO-3107 for the treatment of Recurrent Respiratory Papillomatosis or RRP, is currently being reviewed by FDA under the accelerated approval program. So we have a BLA on file with a target date of October 30 this year.
Credit: Source link
